Semin Respir Crit Care Med 2007; 28(2): 222-242
DOI: 10.1055/s-2007-976494
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Community Respiratory Virus Infections in Immunocompromised Patients: Hematopoietic Stem Cell and Solid Organ Transplant Recipients, and Individuals with Human Immunodeficiency Virus Infection

Yae-Jean Kim1 , 2 , Michael Boeckh1 , Janet A. Englund1 , 3
  • 1Division of Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington
  • 2Department of Pediatrics, Samsung Medical Center, SungKyunKwan University School of Medicine, Seoul, Korea
  • 3Division of Infectious Diseases, Children’s Hospital and Regional Medical Center, Seattle, Washington
Further Information

Publication History

Publication Date:
25 April 2007 (online)

ABSTRACT

Infection is the leading cause of morbidity and mortality in immunocompromised patients such as hematopoietic/solid organ transplant recipients and individuals with human immunodeficiency virus. Community respiratory virus infections are increasingly recognized as a significant threat to these patients. This article reviews current information in the clinical field of community respiratory viruses, including several newly discovered respiratory viruses.

Respiratory syncytial virus, influenza viruses, parainfluenza viruses, and adenoviruses cause the most serious disease in immunocompromised hosts, but other respiratory viruses are becoming increasingly appreciated as a cause of both upper and lower respiratory tract disease. The clinical impact of these new viruses, including human metapneumovirus, non-SARS human coronaviruses, and human bocavirus, is not yet clear. Modern molecular technology has made the discovery of new viruses possible; the use of these new technologies in direct patient care is not yet standard but is becoming increasingly utilized. Clinicians should appreciate the potential for the development of antiviral resistance to influenza antivirals in immunocompromised patients.

REFERENCES

  • 1 Kuypers J, Wright N, Ferrenberg J et al.. Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children.  J Clin Microbiol. 2006;  44 2382-2388
  • 2 Freymuth F, Vabret A, Cuvillon-Nimal D et al.. Comparison of multiplex PCR assays and conventional techniques for the diagnostic of respiratory virus infections in children admitted to hospital with an acute respiratory illness.  J Med Virol. 2006;  78 1498-1504
  • 3 Englund J A, Sullivan C J, Jordan M C, Dehner L P, Vercellotti G M, Balfour Jr H H. Respiratory syncytial virus infection in immunocompromised adults.  Ann Intern Med. 1988;  109 203-208
  • 4 Crooks B N, Taylor C E, Turner A J et al.. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit.  Bone Marrow Transplant. 2000;  26 1097-1102
  • 5 Ljungman P, Ward K N, Crooks B N et al.. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.  Bone Marrow Transplant. 2001;  28 479-484
  • 6 Small T N, Casson A, Malak S F et al.. Respiratory syncytial virus infection following hematopoietic stem cell transplantation.  Bone Marrow Transplant. 2002;  29 321-327
  • 7 Chemaly R F, Ghosh S, Bodey G P et al.. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center.  Medicine (Baltimore). 2006;  85 278-287
  • 8 Whimbey E, Champlin R E, Englund J A et al.. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients.  Bone Marrow Transplant. 1995;  16 393-399
  • 9 Nichols W G, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience.  Biol Blood Marrow Transplant. 2001;  7(Suppl) 11S-15S
  • 10 Whimbey E, Bodey G P. Viral pneumonia in the immunocompromised adult with neoplastic disease: the role of common community respiratory viruses.  Semin Respir Infect. 1992;  7 122-131
  • 11 Whimbey E, Champlin R E, Couch R B et al.. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients.  Clin Infect Dis. 1996;  22 778-782
  • 12 Englund J A. Diagnosis and epidemiology of community-acquired respiratory virus infections in the immunocompromised host.  Biol Blood Marrow Transplant. 2001;  7(Suppl) 2S-4S
  • 13 Erard V, Chien J W, Kim H W et al.. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses.  J Infect Dis. 2006;  193 1619-1625
  • 14 Wendt C H. Community respiratory viruses: organ transplant recipients.  Am J Med. 1997;  102(3A) 31-36 discussion 42-43
  • 15 Sinnott IV J R, Cullison J P, Sweeney M S, Hammond M, Holt D A. Respiratory syncytial virus pneumonia in a cardiac transplant recipient.  J Infect Dis. 1988;  158 650-651
  • 16 Peigue-Lafeuille H, Gazuy N, Mignot P, Deteix P, Beytout D, Baguet J C. Severe respiratory syncytial virus pneumonia in an adult renal transplant recipient: successful treatment with ribavirin.  Scand J Infect Dis. 1990;  22 87-89
  • 17 Pohl C, Green M, Wald E R, Ledesma-Medina J. Respiratory syncytial virus infections in pediatric liver transplant recipients.  J Infect Dis. 1992;  165 166-169
  • 18 Blanchard S S, Gerrek M, Siegel C, Czinn S J. Significant morbidity associated with RSV infection in immunosuppressed children following liver transplantation: case report and discussion regarding need of routine prophylaxis.  Pediatr Transplant. 2006;  10 826-829
  • 19 Wendt C H, Fox J M, Hertz M I. Paramyxovirus infection in lung transplant recipients.  J Heart Lung Transplant. 1995;  14 479-485
  • 20 Kumar D, Erdman D, Keshavjee S et al.. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant.  Am J Transplant. 2005;  5 2031-2036
  • 21 Harrington R D, Hooton T M, Hackman R C et al.. An outbreak of respiratory syncytial virus in a bone marrow transplant center.  J Infect Dis. 1992;  165 987-993
  • 22 Hertz M I, Englund J A, Snover D, Bitterman P B, McGlave P B. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature.  Medicine (Baltimore). 1989;  68 269-281
  • 23 Fouillard L, Mouthon L, Laporte J P et al.. Severe respiratory syncytial virus pneumonia after autologous bone marrow transplantation: a report of three cases and review.  Bone Marrow Transplant. 1992;  9 97-100
  • 24 Abdallah A, Rowland K E, Schepetiuk S K, To L B, Bardy P. An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: effect on engraftment and outcome of pneumonia without specific antiviral treatment.  Bone Marrow Transplant. 2003;  32 195-203
  • 25 Raad I, Abbas J, Whimbey E. Infection control of nosocomial respiratory viral disease in the immunocompromised host.  Am J Med. 1997;  102(3A) 48-52 discussion 3-4
  • 26 Tablan O C, Anderson L J, Besser R, Bridges C, Hajjeh R. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee.  MMWR Recomm Rep. 2004;  53(RR-3) 1-36
  • 27 Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.  Pediatrics. 1998;  102(3 Pt 1) 531-537
  • 27a Wu H, Pfarr D S, Johnson S et al.. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.  J Mol Biol. , 2007 Feb 20 [Epub ahead of print]
  • 28 Dall'Acqua W F, Kiener P A, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).  J Biol Chem. 2006;  281 23514-23524
  • 29 Mejias A, Chavez-Bueno S, Rios A M et al.. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.  Antimicrob Agents Chemother. 2005;  49 4700-4707
  • 30 Ghosh S, Champlin R E, Englund J et al.. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin.  Bone Marrow Transplant. 2000;  25 751-755
  • 31 Cortez K, Murphy B R, Almeida K N et al.. Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation.  J Infect Dis. 2002;  186 834-838
  • 32 Boeckh M, Berrey M M, Bowden R A, Crawford S W, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.  J Infect Dis. 2001;  184 350-354
  • 33 Peck A J, Corey L, Boeckh M. Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation.  Clin Infect Dis. 2004;  39 673-680
  • 34 Bowden R A. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience.  Am J Med. 1997;  102(3A) 27-30 discussion 42-43
  • 35 Whimbey E, Englund J A, Couch R B. Community respiratory virus infections in immunocompromised patients with cancer.  Am J Med. 1997;  102(3A) 10-18 discussion 25-26
  • 36 Boeckh M, Englund J, Carpenter M et al.. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients.  Clin Infect Dis. 2007;  44 245-249
  • 37 Gruber W C, Wilson S Z, Throop B J, Wyde P R. Immunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection of the cotton rat.  Pediatr Res. 1987;  21 270-274
  • 38 Hemming V G, Rodriguez W, Kim H W et al.. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children.  Antimicrob Agents Chemother. 1987;  31 1882-1886
  • 39 De Vincenzo J P, Leombruno D, Soiffer R J, Siber G R. Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation.  Bone Marrow Transplant. 1996;  17 1051-1056
  • 40 Rodriguez W J, Gruber W C, Welliver R C et al.. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.  Pediatrics. 1997;  99 454-461
  • 41 Lewinsohn D M, Bowden R A, Mattson D, Crawford S W. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation.  Antimicrob Agents Chemother. 1996;  40 2555-2557
  • 42 Englund J A, Piedra P A, Whimbey E. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients.  Am J Med. 1997;  102(3A) 61-70 discussion 5-6
  • 43 Sparrelid E, Ljungman P, Ekelof-Andstrom E et al.. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections.  Bone Marrow Transplant. 1997;  19 905-908
  • 44 Glanville A R, Scott A I, Morton J M et al.. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation.  J Heart Lung Transplant. 2005;  24 2114-2119
  • 45 Anaissie E J, Mahfouz T H, Aslan T et al.. The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management.  Blood. 2004;  103 1611-1617
  • 46 Peck A, Englund J, Kuypers J et al.. Asymptomatic respiratory virus infection among hematopoietic cell recipients. 43rd Annual Meeting of Infectious Diseases Society of America, San Francisco, CA, USA 2005 Poster no. 710
  • 47 Elting L S, Whimbey E, Lo W, Couch R, Andreeff M, Bodey G P. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia.  Support Care Cancer. 1995;  3 198-202
  • 48 Yousuf H M, Englund J, Couch R et al.. Influenza among hospitalized adults with leukemia.  Clin Infect Dis. 1997;  24 1095-1099
  • 49 Englund J A. Antiviral therapy of influenza.  Semin Pediatr Infect Dis. 2002;  13 120-128
  • 50 Hassan I A, Chopra R, Swindell R, Mutton K J. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie Hospital experience.  Bone Marrow Transplant. 2003;  32 73-77
  • 51 Raboni S M, Nogueira M B, Tsuchiya L R et al.. Respiratory tract viral infections in bone marrow transplant patients.  Transplantation. 2003;  76 142-146
  • 52 Milstone A P, Brumble L M, Barnes J et al.. A single-season prospective study of respiratory viral infections in lung transplant recipients.  Eur Respir J. 2006;  28 131-137
  • 53 Nichols W G, Guthrie K A, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy.  Clin Infect Dis. 2004;  39 1300-1306
  • 54 Ison M G, Hayden F G. Viral infections in immunocompromised patients: what's new with respiratory viruses?.  Curr Opin Infect Dis. 2002;  15 355-367
  • 55 Smith N M, Bresee J S, Shay D K, Uyeki T M, Cox N J, Strikas R A. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2006;  55(RR-10) 1-42
  • 56 Apalsch A M, Green M, Ledesma-Medina J, Nour B, Wald E R. Parainfluenza and influenza virus infections in pediatric organ transplant recipients.  Clin Infect Dis. 1995;  20 394-399
  • 57 Mauch T J, Bratton S, Myers T, Krane E, Gentry S R, Kashtan C E. Influenza B virus infection in pediatric solid organ transplant recipients.  Pediatrics. 1994;  94(2 Pt 1) 225-229
  • 58 Briggs J D, Timbury M C, Paton A M, Bell P R. Viral infection and renal transplant rejection.  BMJ. 1972;  4 520-522
  • 59 Gabriel R, Selwyn S, Brown D et al.. Virus infections and acute renal transplant rejection.  Nephron. 1976;  16 282-286
  • 60 Hohlfeld J, Niedermeyer J, Hamm H, Schafers H J, Wagner T O, Fabel H. Seasonal onset of bronchiolitis obliterans syndrome in lung transplant recipients.  J Heart Lung Transplant. 1996;  15 888-894
  • 61 Vilchez R, McCurry K, Dauber J et al.. Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients.  Transplantation. 2002;  73 1075-1078
  • 62 Vilchez R A, McCurry K, Dauber J et al.. Influenza virus infection in adult solid organ transplant recipients.  Am J Transplant. 2002;  2 287-291
  • 63 Duchini A, Goss J A, Karpen S, Pockros P J. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols.  Clin Microbiol Rev. 2003;  16 357-364
  • 64 Sullivan K M, Dykewicz C A, Longworth D L et al.. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond.  Hematology (Am Soc Hematol Educ Program). 2001;  392-421
  • 65 Machado C M, Cardoso M R, da Rocha I F, Boas L S, Dulley F L, Pannuti C S. The benefit of influenza vaccination after bone marrow transplantation.  Bone Marrow Transplant. 2005;  36 897-900
  • 66 Engelhard D, Nagler A, Hardan I et al.. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients.  Bone Marrow Transplant. 1993;  11 1-5
  • 67 Somani J, Larson R A. Reimmunization after allogeneic bone marrow transplantation.  Am J Med. 1995;  98 389-398
  • 68 Ljungman P, Cordonnier C, de Bock R et al.. Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation.  Bone Marrow Transplant. 1995;  15 455-460
  • 69 Avetisyan G, Ragnavolgyi E, Toth G T, Hassan M, Ljungman P. Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients.  Bone Marrow Transplant. 2005;  36 411-415
  • 70 Haining W N, Evans J W, Seth N P et al.. Measuring T cell immunity to influenza vaccination in children after haematopoietic stem cell transplantation.  Br J Haematol. 2004;  127 322-325
  • 71 Mazzone P J, Mossad S B, Mawhorter S D, Mehta A C, Mauer J R. Cell-mediated immune response to influenza vaccination in lung transplant recipients.  J Heart Lung Transplant. 2004;  23 1175-1181
  • 72 Pauksen K, Linde A, Hammarstrom V et al.. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients.  Clin Infect Dis. 2000;  30 342-348
  • 73 Ramanathan R K, Potter D M, Belani C P et al.. Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients.  J Clin Oncol. 2002;  20 4313-4318
  • 74 Bright R A, Shay D K, Shu B, Cox N J, Klimov A I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States.  JAMA. 2006;  295 891-894
  • 75 Hayden F G. Antiviral resistance in influenza viruses: implications for management and pandemic response.  N Engl J Med. 2006;  354 785-788
  • 76 Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review.  Lancet. 2006;  367 303-313
  • 77 Vu D, Nichols W G, Barley C, Englund J A, Corey L, Boeckh M. Oseltamivir Prophylaxis in Hematopoietic Cell Transplantation Recipients: A Case-Control Study 44th Annual Meeting of Infectious Diseases Society of America Toronto, Ontario, Canada 2006 Poster no. 816
  • 78 Hayden F G, Osterhaus A D, Treanor J J et al.. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of Influenzavirus infections. GG167 Influenza Study Group.  N Engl J Med. 1997;  337 874-880
  • 79 Hayden F G, Treanor J J, Fritz R S et al.. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.  JAMA. 1999;  282 1240-1246
  • 80 Treanor J J, Hayden F G, Vrooman P S et al.. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.  JAMA. 2000;  283 1016-1024
  • 81 Whitley R J, Hayden F G, Reisinger K S et al.. Oral oseltamivir treatment of influenza in children.  Pediatr Infect Dis J. 2001;  20 127-133
  • 81a Nichols W G, Guthrie K A, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy.  Clin Infect Dis. 2004;  39 1300-1306
  • 82 Kiso M, Mitamura K, Sakai-Tagawa Y et al.. Resistant influenza A viruses in children treated with oseltamivir: descriptive study.  Lancet. 2004;  364 759-765
  • 83 Ison M G, Gubareva L V, Atmar R L, Treanor J, Hayden F G. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series.  J Infect Dis. 2006;  193 760-764
  • 84 Monto A S, McKimm-Breschkin J L, Macken C et al.. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.  Antimicrob Agents Chemother. 2006;  50 2395-2402
  • 85 Ison M G, Gnann Jr J W, Nagy-Agren S et al.. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza.  Antivir Ther. 2003;  8 183-190
  • 86 Hayden F G. Combination antiviral therapy for respiratory virus infections.  Antiviral Res. 1996;  29 45-48
  • 87 Chanock R M, Parrott R H, Johnson K M, Kapikian A Z, Bell J A. Myxoviruses: parainfluenza.  Am Rev Respir Dis. 1963;  88(Suppl) 152-166
  • 88 Wendt C H, Weisdorf D J, Jordan M C, Balfour Jr H H, Hertz M I. Parainfluenza virus respiratory infection after bone marrow transplantation.  N Engl J Med. 1992;  326 921-926
  • 89 Ljungman P. Respiratory virus infections in bone marrow transplant recipients: the European perspective.  Am J Med. 1997;  102(3A) 44-47
  • 90 Lewis V A, Champlin R, Englund J et al.. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients.  Clin Infect Dis. 1996;  23 1033-1037
  • 91 Whimbey E, Vartivarian S E, Champlin R E, Elting L S, Luna M, Bodey G P. Parainfluenza virus infection in adult bone marrow transplant recipients.  Eur J Clin Microbiol Infect Dis. 1993;  12 699-701
  • 92 Nichols W G, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome.  Blood. 2001;  98 573-578
  • 93 Dignan F, Alvares C, Riley U et al.. Parainfluenza type 3 infection post stem cell transplant: high prevalence but low mortality.  J Hosp Infect. 2006;  63 452-458
  • 94 Nichols W G, Erdman D D, Han A, Zukerman C, Corey L, Boeckh M. Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis.  Biol Blood Marrow Transplant. 2004;  10 58-64
  • 95 Vilchez R A, McCurry K, Dauber J et al.. The epidemiology of parainfluenza virus infection in lung transplant recipients.  Clin Infect Dis. 2001;  33 2004-2008
  • 96 Ottolini M G, Hemming V G, Piazza F M, Johnson S A, Darnell M E, Prince G A. Topical immunoglobulin is an effective therapy for parainfluenza type 3 in a cotton rat model.  J Infect Dis. 1995;  172 243-245
  • 97 Karron R A, Belshe R B, Wright P F et al.. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.  Pediatr Infect Dis J. 2003;  22 394-405
  • 98 Belshe R B, Newman F K, Tsai T F et al.. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.  J Infect Dis. 2004;  189 462-470
  • 99 Ottolini M G, Porter D D, Blanco J C, Prince G A. A cotton rat model of human parainfluenza 3 laryngotracheitis: virus growth, pathology, and therapy.  J Infect Dis. 2002;  186 1713-1717
  • 100 Frank Jr J A, Warren R W, Tucker J A, Zeller J, Wilfert C M. Disseminated parainfluenza infection in a child with severe combined immunodeficiency.  Am J Dis Child. 1983;  137 1172-1174
  • 101 Wright J J, O'Driscoll G. Treatment of parainfluenza virus 3 pneumonia in a cardiac transplant recipient with intravenous ribavirin and methylprednisolone.  J Heart Lung Transplant. 2005;  24 343-346
  • 102 Carballal G, Videla C, Misirlian A, Requeijo P V, Aguilar Mdel C. Adenovirus type 7 associated with severe and fatal acute lower respiratory infections in Argentine children.  BMC Pediatr. 2002;  2 6
  • 103 Hong J Y, Lee H J, Piedra P A et al.. Lower respiratory tract infections due to adenovirus in hospitalized Korean children: epidemiology, clinical features, and prognosis.  Clin Infect Dis. 2001;  32 1423-1429
  • 104 Barker J H, Luby J P, Sean Dalley A, Bartek W M, Burns D K, Erdman D D. Fatal type 3 adenoviral pneumonia in immunocompetent adult identical twins.  Clin Infect Dis. 2003;  37 e142-e146
  • 105 Chuang Y Y, Chiu C H, Wong K S et al.. Severe adenovirus infection in children.  J Microbiol Immunol Infect. 2003;  36 37-40
  • 106 Ison M G. Adenovirus infections in transplant recipients.  Clin Infect Dis. 2006;  43 331-339
  • 107 Suparno C, Milligan D W, Moss P A, Mautner V. Adenovirus infections in stem cell transplant recipients: recent developments in understanding of pathogenesis, diagnosis and management.  Leuk Lymphoma. 2004;  45 873-885
  • 108 Hoffman J A, Shah A J, Ross L A, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation.  Biol Blood Marrow Transplant. 2001;  7 388-394
  • 109 Bruno B, Gooley T, Hackman R C, Davis C, Corey L, Boeckh M. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival.  Biol Blood Marrow Transplant. 2003;  9 341-352
  • 110 Baldwin A, Kingman H, Darville M et al.. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation.  Bone Marrow Transplant. 2000;  26 1333-1338
  • 111 de Mezerville M H, Tellier R, Richardson S, Hebert D, Doyle J, Allen U. Adenoviral infections in pediatric transplant recipients: a hospital-based study.  Pediatr Infect Dis J. 2006;  25 815-818
  • 112 Lion T, Baumgartinger R, Watzinger F et al.. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease.  Blood. 2003;  102 1114-1120
  • 113 Leruez-Ville M, Minard V, Lacaille F et al.. Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection.  Clin Infect Dis. 2004;  38 45-52
  • 114 Chakrabarti S, Mautner V, Osman H et al.. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery.  Blood. 2002;  100 1619-1627
  • 115 Schilham M W, Claas E C, van Zaane W et al.. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation.  Clin Infect Dis. 2002;  35 526-532
  • 116 Humar A, Kumar D, Mazzulli T et al.. A surveillance study of adenovirus infection in adult solid organ transplant recipients.  Am J Transplant. 2005;  5 2555-2559
  • 117 Michaels M G, Green M, Wald E R, Starzl T E. Adenovirus infection in pediatric liver transplant recipients.  J Infect Dis. 1992;  165 170-174
  • 118 McGrath D, Falagas M E, Freeman R et al.. Adenovirus infection in adult orthotopic liver transplant recipients: incidence and clinical significance.  J Infect Dis. 1998;  177 459-462
  • 119 Seidemann K, Heim A, Pfister E D et al.. Monitoring of adenovirus infection in pediatric transplant recipients by quantitative PCR: report of six cases and review of the literature.  Am J Transplant. 2004;  4 2102-2108
  • 120 Kaufman S S, Magid M S, Tschernia A, LeLeiko N S, Fishbein T M. Discrimination between acute rejection and adenoviral enteritis in intestinal transplant recipients.  Transplant Proc. 2002;  34 943-945
  • 121 Pinchoff R J, Kaufman S S, Magid M S et al.. Adenovirus infection in pediatric small bowel transplantation recipients.  Transplantation. 2003;  76 183-189
  • 122 Ohori N P, Michaels M G, Jaffe R, Williams P, Yousem S A. Adenovirus pneumonia in lung transplant recipients.  Hum Pathol. 1995;  26 1073-1079
  • 123 Bridges N D, Spray T L, Collins M H, Bowles N E, Towbin J A. Adenovirus infection in the lung results in graft failure after lung transplantation.  J Thorac Cardiovasc Surg. 1998;  116 617-623
  • 124 Shirali G S, Ni J, Chinnock R E et al.. Association of viral genome with graft loss in children after cardiac transplantation.  N Engl J Med. 2001;  344 1498-1503
  • 125 Morfin F, Dupuis-Girod S, Mundweiler S et al.. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent.  Antivir Ther. 2005;  10 225-229
  • 126 Yusuf U, Hale G A, Carr J et al.. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients.  Transplantation. 2006;  81 1398-1404
  • 127 Wallot M A, Dohna-Schwake C, Auth M et al.. Disseminated adenovirus infection with respiratory failure in pediatric liver transplant recipients: impact of intravenous cidofovir and inhaled nitric oxide.  Pediatr Transplant. 2006;  10 121-127
  • 128 Legrand F, Berrebi D, Houhou N et al.. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children.  Bone Marrow Transplant. 2001;  27 621-626
  • 129 Nagafuji K, Aoki K, Henzan H et al.. Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients.  Bone Marrow Transplant. 2004;  34 909-914
  • 130 Hartline C B, Gustin K M, Wan W B et al.. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro.  J Infect Dis. 2005;  191 396-399
  • 131 Lankester A C, Heemskerk B, Claas E C et al.. Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection.  Clin Infect Dis. 2004;  38 1521-1525
  • 132 Feuchtinger T, Matthes-Martin S, Richard C et al.. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation.  Br J Haematol. 2006;  134 64-76
  • 133 van den Hoogen B G, de Jong J C, Groen J et al.. A newly discovered human pneumovirus isolated from young children with respiratory tract disease.  Nat Med. 2001;  7 719-724
  • 134 Falsey A R, Erdman D, Anderson L J, Walsh E E. Human metapneumovirus infections in young and elderly adults.  J Infect Dis. 2003;  187 785-790
  • 135 Williams J V, Crowe Jr J E, Enriquez R et al.. Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults.  J Infect Dis. 2005;  192 1149-1153
  • 136 Williams J V, Harris P A, Tollefson S J et al.. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children.  N Engl J Med. 2004;  350 443-450
  • 137 Williams J V, Wang C K, Yang C F et al.. The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience.  J Infect Dis. 2006;  193 387-395
  • 138 Martino R, Porras R P, Rabella N et al.. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies.  Biol Blood Marrow Transplant. 2005;  11 781-796
  • 139 Sumino K C, Agapov E, Pierce R A et al.. Detection of severe human metapneumovirus infection by real-time polymerase chain reaction and histopathological assessment.  J Infect Dis. 2005;  192 1052-1060
  • 140 Englund J, Boeckh M, Kuypers J et al.. Fatal human metapneumovirus infection in stem cell transplant recipients.  Ann Intern Med. 2006;  144 344-349
  • 141 Williams J V, Martino R, Rabella N et al.. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections.  J Infect Dis. 2005;  192 1061-1065
  • 142 Debiaggi M, Canducci F, Sampaolo M et al.. Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients.  J Infect Dis. 2006;  194 474-478
  • 143 Dare R, Sanghavi S, Bullotta A et al.. Detection of human metapneumovirus (hMPV) infection in immunosuppressed lung transplant recipients and children evaluated for pertussis.  J Clin Microbiol. 2007;  45 548-552
  • 144 Larcher C, Geltner C, Fischer H, Nachbaur D, Muller L C, Huemer H P. Human metapneumovirus infection in lung transplant recipients: clinical presentation and epidemiology.  J Heart Lung Transplant. 2005;  24 1891-1901
  • 145 Wyde P R, Chetty S N, Jewell A M, Boivin G, Piedra P A. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro.  Antiviral Res. 2003;  60 51-59
  • 146 Englund J A, Boeckh M, Kuypers J et al.. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients.  Ann Intern Med. 2006;  144 344-349
  • 147 Tang R S, Mahmood K, Macphail M et al.. A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys.  Vaccine. 2005;  23 1657-1667
  • 148 Cseke G, Wright D W, Tollefson S J, Johnson J E, Crowe Jr J E, Williams J V. Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats.  J Virol. 2007;  81 698-707
  • 149 Johnston S L. Natural and experimental rhinovirus infections of the lower respiratory tract.  Am J Respir Crit Care Med. 1995;  152(4 Pt 2) S46-S52
  • 150 Gern J E, Galagan D M, Jarjour N N, Dick E C, Busse W W. Detection of rhinovirus RNA in lower airway cells during experimentally induced infection.  Am J Respir Crit Care Med. 1997;  155 1159-1161
  • 151 Ghosh S, Champlin R, Couch R et al.. Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients.  Clin Infect Dis. 1999;  29 528-532
  • 152 Ison M G, Hayden F G, Kaiser L, Corey L, Boeckh M. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia.  Clin Infect Dis. 2003;  36 1139-1143
  • 153 Malcolm E, Arruda E, Hayden F G, Kaiser L. Clinical features of patients with acute respiratory illness and rhinovirus in their bronchoalveolar lavages.  J Clin Virol. 2001;  21 9-16
  • 154 Kaiser L, Aubert J D, Pache J C et al.. Chronic rhinoviral infection in lung transplant recipients.  Am J Respir Crit Care Med. 2006;  174 1392-1399
  • 155 Patick A K. Rhinovirus chemotherapy.  Antiviral Res. 2006;  71 391-396
  • 156 Gerna G, Campanini G, Rovida F et al.. Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients.  J Med Virol. 2006;  78 938-949
  • 157 Garbino J, Crespo S, Aubert J D et al.. A prospective hospital-based study of the clinical impact of non-severe acute respiratory syndrome (Non-SARS)-related human coronavirus infection.  Clin Infect Dis. 2006;  43 1009-1015
  • 158 Chakrabarti S, Collingham K E, Stevens R H, Pillay D, Fegan C D, Milligan D W. Isolation of viruses from stools in stem cell transplant recipients: a prospective surveillance study.  Bone Marrow Transplant. 2000;  25 277-282
  • 159 Gonzalez Y, Martino R, Badell I et al.. Pulmonary enterovirus infections in stem cell transplant recipients.  Bone Marrow Transplant. 1999;  23 511-513
  • 160 Tan P L, Verneris M R, Charnas L R, Reck S J, van Burik J A, Blazar B R. Outcome of CNS and pulmonary enteroviral infections after hematopoietic cell transplantation.  Pediatr Blood Cancer. 2005;  45 74-75
  • 161 Winkelstein J A, Marino M C, Lederman H M et al.. X-linked agammaglobulinemia: report on a United States registry of 201 patients.  Medicine (Baltimore). 2006;  85 193-202
  • 162 Donoso Mantke O, Meyer R, Prosch S et al.. High prevalence of cardiotropic viruses in myocardial tissue from explanted hearts of heart transplant recipients and heart donors: a 3-year retrospective study from a German patients’ pool.  J Heart Lung Transplant. 2005;  24 1632-1638
  • 163 Allander T, Tammi M T, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples.  Proc Natl Acad Sci USA. 2005;  102 12891-12896
  • 164 Manning A, Russell V, Eastick K et al.. Epidemiological profile and clinical associations of human bocavirus and other human parvoviruses.  J Infect Dis. 2006;  194 1283-1290
  • 165 Kesebir D, Vazquez M, Weibel C et al.. Human bocavirus infection in young children in the United States: molecular epidemiological profile and clinical characteristics of a newly emerging respiratory virus.  J Infect Dis. 2006;  194 1276-1282
  • 166 Chung J Y, Han T H, Kim C K, Kim S W. Bocavirus infection in hospitalized children, South Korea.  Emerg Infect Dis. 2006;  12 1254-1256
  • 167 Foulongne V, Olejnik Y, Perez V, Elaerts S, Rodiere M, Segondy M. Human bocavirus in French children.  Emerg Infect Dis. 2006;  12 1251-1253
  • 168 Bastien N, Brandt K, Dust K, Ward D, Li Y. Human Bocavirus infection, Canada.  Emerg Infect Dis. 2006;  12 848-850
  • 169 Sloots T P, McErlean P, Speicher D J, Arden K E, Nissen M D, Mackay I M. Evidence of human coronavirus HKU1 and human bocavirus in Australian children.  J Clin Virol. 2006;  35 99-102
  • 170 Kumar D, Humar A. Pandemic influenza and its implications for transplantation.  Am J Transplant. 2006;  6 1512-1517
  • 171 Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients.  MMWR Recomm Rep. 2000;  49(RR-10) 1-128
  • 172 King Jr J C. Community respiratory viruses in individuals with human immunodeficiency virus infection.  Am J Med. 1997;  102(3A) 19-24 discussion 5-6
  • 173 Madhi S A, Schoub B, Simmank K, Blackburn N, Klugman K P. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1.  J Pediatr. 2000;  137 78-84
  • 174 Madhi S A, Venter M, Madhi A, Petersen M K, Klugman K P. Differing manifestations of respiratory syncytial virus-associated severe lower respiratory tract infections in human immunodeficiency virus type 1-infected and uninfected children.  Pediatr Infect Dis J. 2001;  20 164-170
  • 175 Madhi S A, Kuwanda L, Cutland C, Klugman K P. Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children.  J Clin Virol. 2006;  36 215-221
  • 176 Neuzil K M, Coffey C S, Mitchel Jr E F, Griffin M R. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection.  J Acquir Immune Defic Syndr. 2003;  34 304-307
  • 177 Madhi S A, Ramasamy N, Bessellar T G, Saloojee H, Klugman K P. Lower respiratory tract infections associated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection.  Pediatr Infect Dis J. 2002;  21 291-297
  • 178 Malaspina A, Moir S, Orsega S M et al.. Compromised B cell responses to influenza vaccination in HIV-infected individuals.  J Infect Dis. 2005;  191 1442-1450
  • 179 Kroon F P, van Dissel J T, de Jong J C, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study.  Vaccine. 2000;  18 3040-3049
  • 180 Atashili J, Kalilani L, Adimora A A. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis.  BMC Infect Dis. 2006;  6 138
  • 181 Madhi S A, Ramasamy N, Petersen K, Madhi A, Klugman K P. Severe lower respiratory tract infections associated with human parainfluenza viruses 1-3 in children infected and noninfected with HIV type 1.  Eur J Clin Microbiol Infect Dis. 2002;  21 499-505
  • 182 Madhi S A, Ludewick H, Abed Y, Klugman K P, Boivin G. Human metapneumovirus-associated lower respiratory tract infections among hospitalized human immunodeficiency virus type 1 (HIV-1)-infected and HIV-1-uninfected African infants.  Clin Infect Dis. 2003;  37 1705-1710
  • 183 Mendoza Sanchez M C, Ruiz-Contreras J, Vivanco J L et al.. Respiratory virus infections in children with cancer or HIV infection.  J Pediatr Hematol Oncol. 2006;  28 154-159
  • 184 Vilchez R A, Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection-myth or reality?.  Am J Transplant. 2003;  3 245-249
  • 185 Vilchez R A, Dauber J, McCurry K, Iacono A, Kusne S. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function.  Am J Transplant. 2003;  3 116-120
  • 186 Lim A K, Parsons S, Ierino F. Adenovirus tubulointerstitial nephritis presenting as a renal allograft space occupying lesion.  Am J Transplant. 2005;  5 2062-2066
  • 187 Ljungman P, Ribaud P, Eyrich M et al.. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.  Bone Marrow Transplant. 2003;  31 481-486
  • 188 McLaughlin G E, Delis S, Kashimawo L et al.. Adenovirus infection in pediatric liver and intestinal transplant recipients: utility of DNA detection by PCR.  Am J Transplant. 2003;  3 224-228
  • 189 Runde V, Ross S, Trenschel R et al.. Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study.  Bone Marrow Transplant. 2001;  28 51-57
  • 190 Cane P A, van den Hoogen B G, Chakrabarti S, Fegan C D, Osterhaus A D. Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease.  Bone Marrow Transplant. 2003;  31 309-310
  • 191 Lau S K, Woo P C, Yip C C et al.. Coronavirus HKU1 and other coronavirus infections in Hong Kong.  J Clin Microbiol. 2006;  44 2063-2071
  • 192 Arnold J C, Singh K K, Spector S A, Sawyer M H. Human bocavirus: prevalence and clinical spectrum at a children's hospital.  Clin Infect Dis. 2006;  43 283-288
  • 193 Kaplan N M, Dove W, Abu-Zeid A F, Shamoon H E, Abd-Eldayem S A, Hart C A. Human bocavirus infection among children, Jordan.  Emerg Infect Dis. 2006;  12 1418-1420

Janet A EnglundM.D. 

Children’s Hospital and Regional Medical Center

4800 Sand Point Way NE #W8851, Seattle, WA 98105

Email: janet.englund@seattlechildrens.org

    >